Bejel is an infectious rare disease that belongs to spirochete treponema pallidum bacterium family. The organisms cause ulceration (lesions) on mucous membrane (skin), particularly in or near mouth. Also, these organisms progress gradually appear on arms, legs and bones that convert Bejel to most severe stages. Bejel treatment has other symptoms such as lymph nodes or swollen glands, groin and skin ulceration around the rectum. The transmission of these infections is by means skin contact and through common use of drinking & eating utensils. Bejel infection is familiar to syphilis but it is not transmitted sexually. Other related disorders that can be similar to bejel treatment symptoms are Pinta, Yams and Syphilis.
Market Analysis and Insights: Global Bejel Treatment Market
Prior to COVID-19, the market for Bejel Treatment was anticipated to grow from US$ XX million in 2020 to US$ XX million by 2026; it is expected to grow at a CAGR of XX% during 2021–2026, whereas post-COVID-19 scenario, the market for Bejel Treatment is projected to grow from US$ XX million in 2020 (a change by ~XX% compared to market estimated for 2020 before the outbreak of COVID-19) to US$ XX billion by 2026; it is expected to grow at a CAGR of XX% during 2021–2026. The solicitation of proposals by the governments and public–private companies across the world to mitigate the impact of the COVID-19 pandemic is the key factor propelling the growth of the Bejel Treatment market.
Global Bejel Treatment Scope and Segment
The global Bejel Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Bejel Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 200 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Bejel Treatment market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
The major regions covered in the report are North America, Europe, China, Rest of Asia Pacific, Central & South America, Middle East & Africa, etc. It includes revenue analysis of each region for the year 2015 to 2026.
This report also analyzes the impact of Coronavirus COVID-19 on the Bejel Treatment industry.
By the type, the market is primarily split into
Benzathine Penicillin G
Doxycycline
Tetracycline
By the application, this report covers the following segments
Hospitals
Specialty Clinics
Ambulatory Surgery Centers
Drug Stores
Online Pharmacy
Competitive Landscape:
The Bejel Treatment key manufacturers in this market include:
Pfizer
APP Pharmaceuticals
Abcam plc.
Baxter International Inc.
King Pharmaceuticals Inc.
Physicians Total Care Inc.
Alembic IT Department
ECPlaza Network Inc
Sandoz International GmbH
Triveni Interchem Private Limited
CSPC Pharmaceuticals Group Ltd
Semisyntech Co. Ltd
CSC Pharmaceuticals International
Merck KGaA